<DOC>
	<DOCNO>NCT01025648</DOCNO>
	<brief_summary>The main objective study evaluate efficacy safety Armstrong 's Epinephrine HFA-MDI ( E004 ) formulation , comparison Placebo ( Placebo-HFA ) Active Control ( Epinephrine CFC-MDI ) , identify optimum E004 dose strength ( ) ensue pivotal clinical trial . The study conduct adult patient intermittent , mild-to-moderate persistent , asthma , otherwise healthy . The bronchodilatory efficacy E004 , evaluate term post-dose area curve ( AUC ) FEV1 change ( % volumes ) , pre-dose baseline value , comparison Placebo Control Active Control .</brief_summary>
	<brief_title>Randomized , Placebo/Active Crossover Dose-ranging Study Safety Efficacy Asthma Patients .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>1 . Clinical diagnosis intermittent , mildtomoderate persistent , asthma least 6 month Screening , use inhaled epinephrine Î²agonist ( ) asthma control ; 2 . Demonstrating baseline force expiratory volume 1 second ( FEV1 ) 5090 percent predict normal Screening ; 3 . Demonstrating 12.0 percent great airway reversibility FEV1 within 30 min inhale 2 actuation Epinephrine CFCMDI ( 440 mcg Epinephrine base ) Screening ; 4 . Females childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; 5 . Demonstration proficiency use MDI inhaler training ; 6 . Having properly consent participate trial . 1 . A smoking history 10 packyears , smoke within 6 month prior Screening ; 2 . Upper respiratory tract infection within 2 wk , low respiratory tract infection within 4 wk , prior Screening ; 3 . Asthma exacerbation require emergency care hospitalize treatment , within 4 wk prior Screening ; 4 . Any current recent respiratory condition , per investigator discretion , might significantly affect pharmacodynamic response study drug , include cystic fibrosis , bronchiectasis , tuberculosis , emphysema , significant respiratory disease besides asthma ; 5 . Concurrent clinically significant cardiovascular , hematological , renal , neurologic , hepatic , endocrine ( include diabetes ) , psychiatric , neoplastic illness opinion investigator could impact conduct , safety evaluation study ; 6 . Known intolerance hypersensitivity study MDI ingredient ( i.e. , Epinephrine , HFA134a , CFC12 , CFC114 , polysorbate80 , ethanol , thymol , nitric acid ascorbic acid ) ; 7 . Use prohibit drug failure observe drug washout restriction ; 8 . Having investigational drug/device study last 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Mild Moderate Asthma</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>Wheezing</keyword>
	<keyword>Status Asthmaticus</keyword>
</DOC>